3D-QSAR studies on UDP-glucuronosyltransferase 2B7 substrates using the pharmacophore and VolSurf approaches

References

• Aprile S, Del Grosso E, Grosa G. (2010). Identification of the human UDP-glucuronosyltransferases involved in the glucuronidation of combretastatin A-4. Drug Metab Dispos 38:1141–1146.
   PubMed Web of Science ®Google Scholar
• Bae SK, Jeong YJ, Lee C, Liu KH. (2011). Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica 41:437–444.
   PubMed Web of Science ®Google Scholar
• Barre L, Fournel-Gigleux S, Finel M, Netter P, Magdalou J, Ouzzine M. (2007). Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33. FEBS J 274:1256–1264.
   PubMed Web of Science ®Google Scholar
• Bélanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. (2009). Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 37:1793–1796.
   PubMed Web of Science ®Google Scholar
• Berger I, Guttman C, Amar D, Zarivach R, Aharoni A. (2011). The molecular basis for the broad substrate specificity of human sulfotransferase 1A1. PLoS ONE 6:e26794.
   PubMed Web of Science ®Google Scholar
• Blanca Sánchez M, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolas JM, Adín J, Shushtarian M, Armijo JA. (2010). UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 32:177–184.
   PubMed Web of Science ®Google Scholar
• Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO. (2005). S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423–433.
   PubMed Web of Science ®Google Scholar
• Brand W, Boersma MG, Bik H, Hoek-van den Hil EF, Vervoort J, Barron D, Meinl W, Glatt H, Williamson G, van Bladeren PJ, Rietjens IM. (2010). Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab Dispos 38:617–625.
   PubMed Web of Science ®Google Scholar
• Cianchetta G, Mannhold R, Cruciani G, Baroni M, Cecchetti V. (2004). Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach. J Med Chem 47:3193–3201.
   PubMed Web of Science ®Google Scholar
• Crivori P, Cruciani G, Carrupt PA, Testa B. (2000). Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 43:2204–2216.
   PubMed Web of Science ®Google Scholar
• Cruciani G, Crivori P, Carrupt P-A, Testa B. (2000). Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J Mol Struct: THEOCHEM 503:17–30.
   Web of Science ®Google Scholar
• Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA. (2000). Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 28:994–1002.
   PubMed Web of Science ®Google Scholar
• Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, Lazarus P. (2002). Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 62:1978–1986.
   PubMed Web of Science ®Google Scholar
• Foti RS, Fisher MB. (2005). Assessment of UDP-glucuronosyltransferase catalyzed formation of ethyl glucuronide in human liver microsomes and recombinant UGTs. Forensic Sci Int 153:109–116.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Iyer L, Ramírez J, Green MD, Ratain MJ. (2001). Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686–692.
   PubMed Web of Science ®Google Scholar
• Itäaho K, Mackenzie PI, Ikushiro S, Miners JO, Finel M. (2008). The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos 36:2307–2315.
   PubMed Web of Science ®Google Scholar
• John S, Thangapandian S, Sakkiah S, Lee KW. (2011). Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. BMC Bioinformatics 12 Suppl 1:S28.
   PubMedGoogle Scholar
• Kaji H, Kume T. (2005). Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. Drug Metab Dispos 33:403–412.
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A. (2009). Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82–89.
   PubMed Web of Science ®Google Scholar
• Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO. (2009). Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 68:402–412.
   PubMed Web of Science ®Google Scholar
• Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. (2009). CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23:2101–2106.
   PubMed Web of Science ®Google Scholar
• Little JM, Kurkela M, Sonka J, Jäntti S, Ketola R, Bratton S, Finel M, Radominska-Pandya A. (2004). Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases. J Lipid Res 45:1694–1703.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhu J, Chen X, Li N, Fu F, He J, Wang G, Zhang L, Zheng Y, Qiu Z, Yu X, Han D, Wu L. (2009). Identification of human UDP-glucuronosyltransferase isoforms responsible for the glucuronidation of glycyrrhetinic acid. Drug Metab Pharmacokinet 24:523–528.
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677–685.
   PubMed Web of Science ®Google Scholar
• Mano Y, Usui T, Kamimura H. (2007). Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol 63:289–296.
   PubMed Web of Science ®Google Scholar
• Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, Redinbo MR. (2007). Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369:498–511.
   PubMed Web of Science ®Google Scholar
• Oechsler S, Skopp G. (2010). An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation. Int J Legal Med 124:187–194.
   PubMedGoogle Scholar
• Ohkura K, Kawaguchi Y, Watanabe Y, Masubuchi Y, Shinohara Y, Hori H. (2009). Flexible structure of cytochrome P450: promiscuity of ligand binding in the CYP3A4 heme pocket. Anticancer Res 29:935–942.
   PubMed Web of Science ®Google Scholar
• Parmar S, Stingl JC, Huber-Wechselberger A, Kainz A, Renner W, Langsenlehner U, Krippl P, Brockmöller J, Haschke-Becher E. (2011). Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Res 13:R57.
   Google Scholar
• Radominska-Pandya A, Bratton SM, Redinbo MR, Miley MJ. (2010). The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families. Drug Metab Rev 42:133–144.
   PubMed Web of Science ®Google Scholar
• Smith PA, Sorich MJ, Low LS, McKinnon RA, Miners JO. (2004). Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. J Mol Graph Model 22:507–517.
   PubMed Web of Science ®Google Scholar
• Smith PA, Sorich MJ, McKinnon RA, Miners JO. (2003). Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem 46:1617–1626.
   PubMed Web of Science ®Google Scholar
• Soars MG, Ring BJ, Wrighton SA. (2003). The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. Drug Metab Dispos 31:762–767.
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Miners JO, McKinnon RA, Smith PA. (2004). Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol 65:301–308.
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Smith PA, McKinnon RA, Miners JO. (2002). Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 12:635–645.
   PubMedGoogle Scholar
• Staines AG, Coughtrie MW, Burchell B. (2004). N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther 311:1131–1137.
   PubMed Web of Science ®Google Scholar
• Staines AG, Sindelar P, Coughtrie MW, Burchell B. (2004). Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1. Biochem J 384:637–645.
   PubMed Web of Science ®Google Scholar
• Sten T, Qvisen S, Uutela P, Luukkanen L, Kostiainen R, Finel M. (2006). Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab Dispos 34:1488–1494.
   PubMed Web of Science ®Google Scholar
• Turgeon D, Chouinard S, Belanger P, Picard S, Labbe JF, Borgeat P, Belanger A. (2003). Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases. J Lipid Res 44:1182–1191.
   PubMed Web of Science ®Google Scholar
• van der Logt EM, te Morsche RH, Groenendaal N, Roelofs HM, de Metz M, van der Stappen JW, Nagengast FM, Peters WH. (2009). Genetic polymorphism in UDP-glucuronosyltransferase 2B7 and colorectal cancer risk. Oncol Res 17:323–329.
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–1208.
   PubMed Web of Science ®Google Scholar
• Wu B, Basu S, Meng S, Wang X, Hu M. (2011). Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis. Curr Drug Metab 12:900–916.
   PubMed Web of Science ®Google Scholar
• Wu B, Morrow JK, Singh R, Zhang S, Hu M. (2011). Three-dimensional quantitative structure-activity relationship studies on UGT1A9-mediated 3-O-glucuronidation of natural flavonols using a pharmacophore-based comparative molecular field analysis model. J Pharmacol Exp Ther 336:403–413.
   PubMed Web of Science ®Google Scholar
• Wu B, Xu B, Hu M. (2011). Regioselective glucuronidation of flavonols by six human UGT1A isoforms. Pharm Res 28:1905–1918.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhao W, Roongta VA, Mitroka JG, Klunk LJ, Zhu M. (2004). Amide N-glucuronidation of MaxiPost catalyzed by UDP-glucuronosyltransferase 2B7 in humans. Drug Metab Dispos 32:545–551.
   PubMedGoogle Scholar